PLYMOUTH MEETING, Pa., June 15, 2021 /PRNewswire/ -- Braeburn announces that today the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release injection for subcutaneous (SC) use (CIII ...

LUND, Sweden, June 26, 2021 /PRNewswire/ — Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus’ US licensee Braeburn for BrixadiTM (buprenorphine) ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how ...

Please provide your email address to receive an email when new articles are posted on . The FDA tentatively approved certain Brixadi injections for treatment of moderate to severe opioid use disorder, ...

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder OUD is a complex and potentially ...

Brixadi will be supplied as weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) injections. The tentative approval means the FDA concluded Brixadi met all the required safety, efficacy, and ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

pharmacy solutions, announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).